Adocia had agreed with Eli Lilly, a big pharma company, not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology Read the full story

Teva Pharmaceuticals' biotech business collaboration with CureTech Ltd for the CT-011 antibody has been terminated. Read the full story